Proteomic Characterization of Ubiquitin Receptor ADRM1/Rpn13

被引：0
|
作者：
Song, Yan
Du, Ting
Ray, Arghya
Chauhan, Krishan
Samur, Mehmet K.
Chauhan, Dharminder
Anderson, Kenneth
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-139966
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Role of ubiquitin receptor ADRM1 (Rpn13) in prostate cancer
    Chowdhury, Shahjalal
    Wang, Honghe
    Nayak, Chitra
    Karanam, Balasubramanyam
    CANCER RESEARCH, 2024, 84 (06)
  • [2] Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 in Multiple Myeloma
    Song, Yan
    Das, Deepika Sharma
    Ray, Arghya
    Ravillah, Durgadevi
    Munshi, Nikhil C.
    Chauhan, Dharminder
    Anderson, Kenneth C.
    BLOOD, 2014, 124 (21)
  • [3] Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13
    Yan Song
    Ting Du
    Arghya Ray
    Krishan Chauhan
    Mehmet Samur
    Nikhil Munshi
    Dharminder Chauhan
    Kenneth C. Anderson
    Blood Cancer Journal, 11
  • [4] Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13
    Song, Yan
    Du, Ting
    Ray, Arghya
    Chauhan, Krishan
    Samur, Mehmet
    Munshi, Nikhil
    Chauhan, Dharminder
    Anderson, Kenneth C.
    BLOOD CANCER JOURNAL, 2021, 11 (01)
  • [5] A bis-Benzylidine Piperidone Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 as a Therapy for Cancer
    Anchoori, Ravi K.
    Karanam, Balasubramanyam
    Peng, Shiwen
    Wang, Joshua W.
    Jiang, Rosie
    Tanno, Toshihiko
    Orlowski, Robert Z.
    Matsui, William
    Zhao, Ming
    Rudek, Michelle A.
    Hung, Chien-fu
    Chen, Xiang
    Walters, Kylie J.
    Roden, Richard B. S.
    CANCER CELL, 2013, 24 (06) : 791 - 805
  • [6] Targeting Ubiquitin Receptor Rpn13/ADRM1 in Plasmacytoid Dendritic Cells Enhances Anti-Myeloma Immunity
    Ray, Arghya
    Song, Yan
    Du, Ting
    Chauhan, Dharminder
    Anderson, Kenneth C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E133 - E134
  • [7] Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors
    Anchoori, Ravi K.
    George, Logan
    Tseng, Ssu-Hsueh
    Lam, Brandon
    Polkampally, Srinidhi
    Amiano, Anjali D.
    Foran, Palmer
    Tsingine, Hannah
    Samanapally, Harideep
    Carrizo Velasquez, Fernanda
    Das, Samarjit
    Xing, Deyin
    Bin Salam, Ahmad
    Karanam, Balasubramanyam
    Hung, Chien-Fu
    Roden, Richard B. S.
    PLOS ONE, 2021, 16 (09):
  • [8] RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells
    Soong, Ruey-Shyang
    Anchoori, Ravi K.
    Yang, Benjamin
    Yang, Andrew
    Tseng, Ssu-Hsueh
    He, Liangmei
    Tsai, Ya-Chea
    Roden, Richard B. S.
    Hung, Chien-Fu
    ONCOTARGET, 2016, 7 (42) : 68489 - 68502
  • [9] Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor
    Anchoori, Ravi K.
    Anchoori, Vidyasagar
    Lam, Brandon
    Tseng, Ssu-Hsueh
    Das, Samarjit
    Velasquez, Fernanda Carrizo
    Karanam, Balasubramanyam
    Poddatoori, Deepika
    Patnam, Ramesh
    Rudek, Michelle A.
    Chang, Yung-Nien
    Roden, Richard B. S.
    PLOS ONE, 2023, 18 (06):
  • [10] Proteasome subunit Rpn13 is a novel ubiquitin receptor
    Husnjak, Koraljka
    Elsasser, Suzanne
    Zhang, Naixia
    Chen, Xiang
    Randles, Leah
    Shi, Yuan
    Hofmann, Kay
    Walters, Kylie J.
    Finley, Daniel
    Dikic, Ivan
    NATURE, 2008, 453 (7194) : 481 - 488
12345